Ahn-Gook Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
Ahn-Gook Pharmaceutical Co., Ltd.'s Market Cap is ₩1439B. At end of 2025 it was ₩1103B. Ranked #1007 of 2,436 in KR market (top 41%), #499 of 1,649 on KOSDAQ (top 30%), #120 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 143.86B KRW | KR#1,007/2,436 Sec#120/234 |
| Revenue | 330.05B KRW | KR#783/2,436 Sec#36/234 |
| Net Income | 16.21B KRW | KR#724/2,436 Sec#47/234 |
| Total Assets | 326.16B KRW | KR#970/2,436 Sec#62/234 |
| Net Assets | 170.81B KRW | KR#1,021/2,436 Sec#73/234 |
| Employees | 420 | KR#578/2,436 Sec#47/234 |
| Value | ||
| P/E | 8.87x | KR#626/2,436 Sec#28/234 |
| P/B | 0.84x | KR#1,335/2,436 Sec#81/234 |
| PEG | 0.04x | KR#205/2,436 Sec#11/234 |
| P/S | 0.44x | KR#827/2,436 Sec#26/234 |
| EV/EBITDA | 8.35x | KR#488/2,436 Sec#20/234 |
| FCF Yield | 25.87% | KR#238/2,436 Sec#4/234 |
| Profitability | ||
| ROE | 9.49% | KR#548/2,436 Sec#33/234 |
| ROA | 4.97% | KR#657/2,436 Sec#51/234 |
| Op. Margin | 6.06% | KR#793/2,436 Sec#66/234 |
| Revenue Growth | 30.59% | KR#470/2,436 Sec#43/234 |
| Earnings Growth | 253.71% | KR#201/2,436 Sec#13/234 |
| Financial Health | ||
| Debt Ratio | 190.95% | KR#1,640/2,436 Sec#185/234 |
| Total Debt | 72.48B KRW | KR#835/2,436 Sec#59/234 |
| FCF | 37.22B KRW | KR#354/2,436 Sec#20/234 |
| Cash | 49.56B KRW | KR#759/2,436 Sec#48/234 |
| Current Ratio | 1.62x | KR#1,217/2,436 Sec#134/234 |
| Net Debt/EBITDA | 1.15x | KR#812/2,436 Sec#56/234 |
| Dividend | ||
| Div. Yield | 6.03% | KR#196/2,436 Sec#6/234 |
| Div. Growth | 43.86% | KR#262/2,436 Sec#12/234 |
| Performance | ||
| 1Y Return | 41.77% | KR#284/2,436 Sec#24/234 |
| 1M Return | 9.10% | KR#296/2,436 Sec#20/234 |
| From 52W High | -13.35% | KR#85/2,436 Sec#2/234 |
| 1Y MDD | -22.55% | KR#72/2,436 Sec#3/234 |
| Trading | ||
| Volume | 40,073 shares | KR#1,481/2,436 Sec#150/234 |
| Foreign Own. | 3.18% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,247 KRW | KR#547/2,436 Sec#38/234 |
| BPS | 14,946 KRW | KR#659/2,436 Sec#44/234 |
Company Info
Anguk Pharmaceutical, established in 1959, manufactures and sells pharmaceuticals and health functional foods, having been listed on the KOSDAQ market in 2000. It holds several competitive drugs, including Cinechura, Revotension, Revosartan, and Fevarojet, specializing in antitussive expectorant and circulatory system medications. Its Hanam-eup, Hwaseong-si plant, certified by GMP, ensures the production of high-quality pharmaceuticals and engages in contract manufacturing organization (CMO) to maintain stable supply. Anguk Pharmaceutical is headquartered in Gwacheon-si, Gyeonggi-do.